Daiichi Sankyo, a global pharmaceutical company, is seeking novel in vivo models to understand pathological mechanisms in human disease. Indications of interest include microcirculatory disorders (e.g. INOCA, type II myocardial infarction, coronary microvascular dysfunction, etc.), dry aged-macular diseases, psychiatric diseases (neuroinflammatory related model for “CIAS of schizophrenia” and / or “MDD”) and neurodegenerative diseases.
Technology
Academic Researcher
Research Project
Centre of Excellence
Spinout Company
Technology
Academic Researcher
Research Project
Centre of Excellence
Spinout Company
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.